TB/HIV Research Approaches and Challenges Naomi Bock, MD Global AIDS Program Centers for Disease Control and Prevention February 14, 2005.

Slides:



Advertisements
Similar presentations
Unit 1. Introduction TB Infection Control Training for Managers at the National and Subnational Levels.
Advertisements

Expert consultation on TB/HIV research priorities, February 2005 Mesdames et messieurs, soyez les bienvenus On behalf of the organizing committee.
"3 by 5" progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April |2 | Antiretroviral therapy coverage in low-
Ethical issues in Epidemiological Research Dr.Sriyakanthi Beneragama MBBS,MD, Masters in Research Bio-ethics (Australia) Consultant Epidemiologist, National.
TB and HIV: Tightly Linked… and Why We Should Care.
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
Unit 1: Introduction to STI Surveillance in Africa and the Relationship between STIs and HIV #4-1-1.
U. S. Senate Briefing World TB Day Celine Gounder, MD, ScM Center for TB Research, Johns Hopkins University Director for Delivery, CREATE On behalf of.
TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.
00003-E-1 – December 2004 Global summary of the HIV and AIDS epidemic, December 2004 The ranges around the estimates in this table define the boundaries.
Slide 2 Key Points Although HIV/AIDS is found throughout the world, most people living with HIV/AIDS reside in low- and middle-income countries More people.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
00002-E-1 – 1 December 2003 Global summary of the HIV/AIDS epidemic, December 2003 The ranges around the estimates in this table define the boundaries.
UNAIDS World AIDS Day Report | 2011 Core Epidemiology Slides.
Standard of Care for MDR-TB
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
Global Response to HIV/AIDS Nigerian Nurses Association of USA June 30, 2006 Carolyn M Hall, MSN/MPH, ACRN Global HIV/AIDS Program U.S. Department of Health.
HIV and AIDS from UNAIDS / WHO UNAIDS Report on the Global AIDS Epidemic
1 July 2008 e Global summary of the AIDS epidemic, December 2007 Total33 million [30 – 36 million] Adults30.8 million [28.2 – 34.0 million] Women15.5 million.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
2009 ECONOMIC AND SOCIAL COUNCIL ANNUAL MINISTERIAL REVIEW HIV in Latin America and the Caribbean Implementing agreed goals and commitments César Antonio.
Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.
00002-E-1 – 1 December 2002 The AIDS Pandemic: an Update on the Numbers and Needs l What are the numbers for 2002? l What are the global and regional trends?
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
Topical Microbicides Antiviral Drugs Advisory Committee August 20, 2003.
TB/HIV COLLABORATION IN GHANA Dr. Nii Nortey Hanson – Nortey National TB Control Programme Accra.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 2: BACKGROUND ON TUBERCULOSIS Insert country/ministry.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.
00002-E-1 – 1 December 2003 Adults and children estimated to be living with HIV/AIDS as of end 2003 Total: 34 – 46 million Western Europe – 680.
HIV AND INFANT FEEDING A FRAMEWORK FOR PRIORITY ACTIONS.
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases.
00002-E-1 – 1 December 2001 Global summary of the HIV/AIDS epidemic, December 2001 Number of people living with HIV/AIDS Total40 million Adults37.2 million.
1 Total 33.2 million [30.6 – 36.1 million] Adults 30.8 million [28.2 – 33.6 million] Women 15.4 million [13.9 – 16.6 million] Children under 15 years 2.5.
00002-E-1 – 1 December 2002 Global summary of the HIV/AIDS epidemic, December 2002 Number of people living with HIV/AIDS Total42 million Adults38.6 million.
25 Years of AIDS – The Global Response 16 August 2006 XVI International AIDS Conference Toronto.
The Bank’s Regional HIV/AIDS Strategies An Overview.
Estimating the Impact and Needs for Children and PMTCT Making sense: Understanding the numbers: from HIV surveillance to national and global HIV burden.
Global HIV Epidemiology Carey Farquhar, MD, MPH Grace John-Stewart MD, PhD Departments of Medicine, Epidemiology and Global Health.
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.
1 July 2008 e Global summary of the AIDS epidemic, December 2007 Total33 million [30 – 36 million] Adults30.8 million [28.2 – 34.0 million] Women15.5 million.
00002-E-1 – 1 December 2001 THE HIV/AIDS PANDEMIC Focus on Africa By Dr. David Elkins HIV/AIDS Prevention and Care Project Nairobi, Kenya September 2002.
2008 International AIDS Conference UNGASS reporting Matthew Warner-Smith Monitoring and Evaluation Division UNAIDS 2008 International AIDS Conference Satellite.
1 Module 1: [Basic] Unit 1: [HIV Epidemics and Key Populations] Lesson 2: [Levels of HIV Epidemic in the World] “Community-Based HIV Surveillance” Online.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Global Impact of HIV/AIDS Deborah Lewinsohn, M.D. Infectious Diseases, Pediatrics Vaccine and Gene Therapy Institute Oregon Health & Science University.
TB IN THE MINING SECTOR IN SOUTHERN AFRICA
Overview of Global HIV Epidemic
TB- HIV Collaborative activities in Romania- may 2006 status
World Health Organization
XVII International AIDS Conference
TB/HIV surveillance : Who is going to get the job done?
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
"3 by 5" progress December 2005.
Introduction to poster session and discussion
Regional HIV and AIDS statistics 2008 and 2001
Collaborative TB/HIV activities in European Region
The STOP TB Strategy – 2009 VISION: A TB-free world
33rd IUATLD World Conference on Lung Health
TB-HIV/AIDS Co-Infection Coordination among Programs
Strategic framework for TB/HIV
Presentation transcript:

TB/HIV Research Approaches and Challenges Naomi Bock, MD Global AIDS Program Centers for Disease Control and Prevention February 14, 2005

There is a clear complimentarity and inter- relationship between monitoring and evaluation (M&E), some specific surveillance activities and operational research. All derive “strategic information”, new knowledge and data that will make up the evidence base on ART delivery in resource-limited settings.

Approaches (1) D.C. State of Georgia, USA

Information as Intervention Dini et al, J Pub Health Manage Prac, 1996

Assessment Feedback Incentive eXchange Dini et al, J Pub Health Manage Prac, 1996

LeBaron et al, JAMA, 1997 Vaccination Series Completion Rates Georgia Compared with U.S.

Approaches (2) Western Europe – North Africa & Middle East – Sub-Saharan Africa 25.0 – 28.2 million Eastern Europe & Central Asia 1.2 – 1.8 million South & South-East Asia 4.6 – 8.2 million Australia & New Zealand – North America – 1.2 million Caribbean – Latin America 1.3 – 1.9 million East Asia & Pacific – 1.3 million

NNRTI Response Study Observational Study of Treatment Effectiveness and Resistance Patterns among Women Initiating Treatment with Non-nucleoside Reverse- transcriptase Inhibitor-based HAART after Previous Single Dose Nevirapine (SD NVP) in Pregnancy Welcome to the NNRTI Response Study Website. The Epidemiology Branch of the Division of HIV/AIDS Prevention and the Care and Treatment Branch of the Global AIDS Program (GAP), U.S. Centers for Disease Control and Prevention in Atlanta are jointly coordinating this study to examine the response to highly active antiretroviral therapy (HAART) that includes nevirapine (NVP) among women who have been exposed to prior single-dose (SD) NVP as compared to those who have not. This is a prospective observational study consistent with the goal to conduct clinically applicable operational research that is expected to directly inform program implementation. This study will be conducted in at least 2 sites, including Zambia and in Thailand, under the direction of the Principal Investigators listed. The sites where the study will be conducted are providing non-nucleoside reverse transcriptase inhibitors (NNRTI)-based HAART to persons attending their clinics. Some of the women attending these clinics have received SD-NVP for PMTCT in the past and others have not. This study intends to use the opportunity that has been presented at the early stage of a period of rapid expansion of antiretroviral therapy in resource- constrained settings to generate data to address the important question of response to NNRTI-based HAART therapy among women who have received SD-NVP for PMTCT as compared to women who have not. HOME CALENDAR CONTACT US PROTOCOL PROJECT MANUAL FORMS CODE BOOKS PROGRESS REPORTS

International Union Against Tuberculosis and Lung Disease Study A Report of a Controlled Clinical Trial of Two Durations of Chemotherapy for the Treatment of Tuberculosis Amina Jindani, Andrew Nunn, Donald Enarson For the Clinical Trials Programme Investigators †

The TB Trials Consortium (TBTC) Funded since 1998 by the Division of TB Elimination, CDC 28 clinical sites worldwide Links to local TB control programs TBTC Mission: “… to conduct programmatically relevant clinical, laboratory, and epidemiologic research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease.”TBTC Mission: “… to conduct programmatically relevant clinical, laboratory, and epidemiologic research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease.”

28 clinical sites worldwide CDC Administrative, Statistical, and Data Management Center Rio de Janeiro Barcelona Kampala Durban

Database on global MDR-TB research activities Background Currently, there is a lack of evidence available to develop policy recommendations for the management of multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income settings. As a result, WHO and partners developed the DOTS-Plus strategy which is currently being tested through pilot projects and operational research activities. In order to stimulate global MDR-TB research activities the Stop TB Working Group on DOTS-Plus for MDR-TB has developed a prioritised research agenda for DOTS- Plus. -A prioritised research agenda for DOTS-Plus for multidrug-resistantA prioritised research agenda for DOTS-Plus for multidrug-resistant -tuberculosis (MDR-TB) [pdf 51kb] The Stop TB Working Group on DOTS-Plus for MDR-TB. Internationaltuberculosis (MDR-TB) [pdf 51kb] -Journal of Tuberculosis and Lung Disease 2003, 7(5): In addition, a database on global MDR-TB research activities has been created with the following purpose: World Health Organization Home About WHO Countries Health Topics Publications Research tools WHO sites WHO> WHO sites

DOTS Plus and the Green Light Committee WHAT IS DOTS-PLUS? Based upon DOTS, DOTS-Plus is a comprehensive management strategy under development and testing that includes the five tenets of the DOTS strategy. DOTS-Plus takes into account specific issues (such as the use of second-line anti-TB drugs) that need to be addressed in areas where there is high prevalence of MDR-TB. Thus, DOTS-Plus works as a supplement to the standard DOTS strategy. By definition, it is impossible to conduct DOTS-Plus in an area without having an effective DOTS-based TB control programme in place.... WHAT IS THE GREEN LIGHT COMMITTEE? World Health Organization Home About WHO Countries Health Topics Publications Research tools WHO sites WHO> WHO sites

Feedback loop Program implementation Evaluation and operations research Policy definition/revision

Challenges Local involvement Protection of human subjects

Local Involvement National / District / Local programs involved in planning as well as implementation Strengthen TB programs Avoid redirecting scarce resources Include the community of people with TB and HIV

Local Involvement National / District / Local programs involved in planning as well as implementation Strengthen TB programs Avoid redirecting scarce resources Include the community of people with TB and HIV HIV programs involved in planning, implementation, evaluation, policy

Feedback loop Program implementation Evaluation and operations research Policy definition/revision

Feedback loop Program implementation Evaluation and operations research Policy definition/revision

Challenges Local Involvement Protection of human subjects

Declaration of Helsinki “Concern for the interests of the subject must always prevail over the interests of science and society.” 1975 revision

Tuskegee Study of Untreated Syphilis Conducted –To study the natural history of untreated latent syphilis –By US Public Health Service, with support from the Milbank Memorial Fund –Beginning in 1932

Non-therapeutic lumbar puncture

Tuskegee Syphilis Ad Hoc Panel, 1973 No informed consent Vulnerable population Undue inducements - burial costs Participants not informed when penicillin therapy became available in the 1950s Participants systematically blocked from receiving treatment

In 1997, surviving participants of the Tuskegee Syphilis Study and their families gathered at the White House to witness the President's apology on behalf of the United States government

Proposed Roles of WHO Database of research studies GLC approach to those programs interested in participating in research –Program strengthening with partners –DTBE/CDC and Union operational research courses

Proposed Roles of WHO (2) Facilitating human resource expansion –Identifying training grants which fund masters or doctoral students for in-country research –Stimulating donors to create more such programs “Club” of National/District/local programs participating in research at program level, including multi-centre research